



## Prevalence and Gene Expression Variation of Pathogenic Hemolysin Producing *E. coli* Isolated From Patients with Urinary Tract Infections and Diarrhea

Maath Thaer Nejres , Halah Abdulkhaliq Awadh

Department of Biology, Collage of Science, Tikrit University, Tikrit, Iraq

Received: 25 Aug. 2024 Received in revised form: 2 Oct. 2024 Accepted: 17 Oct. 2024

Final Proofreading: 30 Oct. 2024 Available online: 25 Apr. 2025

### ABSTRACT

The *hlyA* gene in *Escherichia coli* (*E. coli*) bacteria codes for the protein hemolysin, which is a toxin produced by these bacteria and contributes to their ability to cause disease. Hemolysin is part of the bacteria's mechanism to increase their harmful effect by lysis red blood cells releasing hemoglobin. This toxin creates holes in the host cell membrane, leading to leakage of cell components and eventual death. The main objective of the current study is to investigate the presence and gene expression of hemolysin toxin genes in *E. coli* isolates from clinical infection cases, including samples from urinary tract infection and diarrhea from patients in Tikrit city, using real-time polymerase chain reaction (RT-PCR) technique. The study was carried out on 50 isolates, divided into 20 isolates from urinary tract infections, 20 isolates from diarrhea cases and 10 isolates as control samples (stool samples from healthy people without diarrhea). The overall prevalence of hemolysin in *E. coli* isolates was 18 out of 40 (45 %). The occurrence of hemolysin-producing *E. coli* isolates detected by RT-PCR was 10 out of 20 (50 %) in urinary tract infection samples and 8 out of 20 (40 %) in diarrhea samples. The production of the hemolysin toxin by *E. coli* isolates varies depending on the type of sample. The results also showed that the gene expression level of hemolysin gene was higher in cases of urinary tract infections compared to cases of diarrhea, with the gene expression level being (Mean folding = 5.933) in urinary tract infection cases, while it was (Mean folding = 3.712) in diarrhea cases, with significant differences at a probability level of (P value  $\leq$  0.05). The results showed that the prevalence of the gene responsible for the secretion of hemolysin toxins by *E. coli* is higher in cases of urinary tract infection (UTIs) than in cases of diarrhea. and the gene expression level of the *hlyA* gene showed a significant increase in cases of urinary tract infections compared to cases of diarrhea.

**Keywords:** Gene expression, Hemolysin, *E. coli*, Real time PCR

**Name:** Maath Thaer Nejres

**E-mail:** [maath.thaer@st.tu.edu.iq](mailto:maath.thaer@st.tu.edu.iq)



©2025 THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE  
<http://creativecommons.org/licenses/by/4.0/>

## مدى انتشار وتباين التعبير الجيني للإشريكية القولونية الممرضة المنتجة لسموم الهيموليسين والمعزولة من المرضى المصابين بالتهابات المسالك البولية والإسهال

معاذ ثائر نجريس، هالة عبد الخالق عوض

قسم علوم الحياة، كلية العلوم، جامعة تكريت، تكريت، العراق

### الملخص

يقوم جين *hlyA* الموجود في بكتيريا *E. coli* بتشفير بروتين الهيموليسين، وهو مادة سامة تنتجها هذه البكتيريا ويساهم في قدرتها على التسبب في المرض. الهيموليسين هو جزء من آلية البكتيريا لزيادة تأثيرها الضار عن طريق تحليل خلايا الدم الحمراء وإطلاق الهيموجلوبين. يحدث هذا السم تقوياً في غشاء الخلية المضيفة، مما يؤدي إلى تسرب مكونات الخلية والموت في نهاية المطاف. هدفت الدراسة الحالية إلى الكشف عن مدى الانتشار والتعبير الجيني لسم الهيموليسين في عزلات بكتيريا الإشريكية القولونية (*E. coli*) من حالات العدوى السريرية المتمثلة عينات التهاب المسالك البولية وعينات الإسهال من المرضى في مدينة تكريت، باستخدام تقنية تفاعل البلمرة المتسلسل اللحظي (Real time PCR). عزلت في الدراسة 50 عزلة *E. coli*، 20 عزلة من التهابات المسالك البولية، و20 عزلة من حالات الإسهال، و10 عينات كمجموعة سيطرة (عينات براز من أشخاص أصحاء غير مصابين بالإسهال). وظهرت النتائج أن نسبة انتشار الهيموليسين في عزلات الإشريكية القولونية الممرضة 18 من أصل 40 (45%). وكانت نسبة وجود عزلات الإشريكية القولونية المنتجة للهيموليسين التي تم الكشف عنها بواسطة تقنية PCR في الوقت الحقيقي هي 10 من أصل 20 (50%) في عينات التهاب المسالك البولية و8 من أصل 20 (40%) في عينات الإسهال. كما أظهرت النتائج أن معدل التعبير الجيني لجين الهيموليسين كان أعلى في حالة الإصابة بالتهابات المسالك البولية مما عليه في حالة الإصابة بالإسهال، حيث بلغ معدل التعبير الجيني (5.933) في حالات التهاب المسالك البولية بينما كانت (3.712) في حالات الإسهال مع وجود فروقات معنوية عند مستوى احتمالية ( $P \text{ value} \leq 0.05$ ). أظهرت النتائج أن نسبة انتشار الجين المسؤول عن إفراز سموم الهيموليسين بواسطة الإشريكية القولونية أعلى في حالات التهابات المسالك البولية مقارنة بحالات الإسهال. وأظهر مستوى التعبير الجيني للجين *hlyA* ارتفاعاً معنوياً في حالات التهابات المسالك البولية مقارنة بحالات الإسهال.

### INTRODUCTION

Urinary tract infection (UTI) is defined as the presence of microorganisms in urine <sup>(1)</sup>. The detection of microbes within the bladder signifies an infection, given that the bladder is inherently a sterile organ <sup>(2)</sup>. UTIs are among the most common types of community-acquired and nosocomial infections, with a significant proportion of the population and individuals of all ages affected annually, host factors such as patients age and gender may influence the prevalence of the infection <sup>(3,4)</sup>. The infection can occur in any part of the urinary system and may be present with or

without symptoms <sup>(5)</sup>. Considerably, UTIs are among the most prevalent types of infections in the body, where women are highly susceptible to this type of infections in comparison with men due to their shorter urethra, which allows bacteria to reach the bladder more swiftly. Additionally, female urethra is open and located near the anus and vagina <sup>(6)</sup>. Generally, *E. coli* are the primary cause of UTIs, traveling from the urinary tract to the bladder, causing cystitis, and then to the kidneys and ureters, leading to pyelonephritis <sup>(7)</sup>. Under health condition, urine is normally sterile and germ-free when it exits

the kidneys, however, it becomes contaminated with bacteria from the skin as it passes through the urethra, allowing bacteria to accumulate. Several factors increase the risk of UTIs, including pregnancy, diabetes, frequent sexual intercourse, prostate enlargement, repeated use of antibiotics, and the use of urinary catheters<sup>(8)</sup>. When bacteria enter the bladder and proliferate in the urine they trigger UTIs, the most common being cystitis, which is characterized by an inability to urinate or frequent, painful urination in the pelvic area. The severity of UTIs depends mainly on bacterial virulence factors and host susceptibility. Microscopic examination and laboratory culture of urine are essential diagnostic tests for detection of UTIs<sup>(9)</sup>. On the other hand, diarrhea is one of the most prevalent health issues globally, particularly in developing countries. It primarily affects children, especially infants, due to conditions associated with poverty, lack of health education, malnutrition, and the unavailability of safe drinking water. Diarrhea is a leading cause of child mortality, particularly among young children<sup>(10)</sup>. The word "Diarrhea" originates from the Greek words "Dia" meaning "through" and "Rhein" meaning "flow". It is a common medical condition characterized by increased frequency of bowel movements and increased stool liquidity<sup>(11, 12)</sup>. If diarrhea lasts less than 14 days, it is termed "acute diarrhea". If it persists or exceeds this duration, it is considered "persistent diarrhea", and if it lasts more than 30 days, it is referred to as "chronic diarrhea". Notably, diarrhea claims the lives of nearly 2 million children under the age of five each year. The illness can last for several days, leading to the deprivation of water and salts that the body needs to survive, with most deaths resulting from severe dehydration. Malnourished individuals, those with weakened immune systems, or those infected with the human immunodeficiency virus (HIV) are at higher risk of dying from diarrhea<sup>(13)</sup>. Hemolysin gene is considered as one of the most significant virulence factors for *E. coli*. There are two types of this toxin:

$\alpha$ -hemolysin and  $\beta$ -hemolysin. The latter are cytotoxins that create pores in the host cell membrane and are encoded by about (40-50 %) of Uropathogenic *E. coli* (UPEC) isolates. It has been shown that the expression of  $\alpha$ -hemolysin increases the severity of clinical symptoms of UTIs. The activity of hemolysin is not limited against red blood cells;  $\alpha$ -hemolysin in *E. coli* lyses lymphocytes, while  $\beta$ -hemolysin inhibits phagocytosis<sup>(14)</sup>. The high incidence of hemolysin-producing strains isolated from urine may indicate their importance as invasive strains<sup>(15)</sup>. Some *E. coli* isolates carry *hlyA* gene, which encodes the hemolysin toxin that secreted extracellularly from bacteria. *E. coli* produce hemolysin toxins in varying quantities, leading to different levels of effect on tissues. Additionally, the expression of *hlyA* gene differs depending on the type of isolate and other factors such as various environmental factors that trigger an increase or a reduction in the production of hemolysin. Temperature, pH, and osmolarity determine the rates and times of fluctuations in hemolysin synthesis<sup>(16, 17)</sup>. An examination of the expression of the hemolysin toxin gene in *E. coli* isolates collected from infection of the urinary tract and diarrhea cases is the main objective of this work.

## MATERIALS AND METHODS

Fifteen *E. coli* isolates were obtained from different sources in Tikrit Teaching Hospital from August 2023 to December 2023, where 20 isolates were isolated from UTIs cases, 20 isolates from diarrhea cases and 10 isolates as control sample were obtained. The diagnosis of the bacterial isolates was confirmed by examining their diagnostic characteristics on blood agar (for identification and as a primary detection of hemolysine producer isolate), MacConkey agar and Eosine methylene blue agar, as well as through biochemical tests like Indole, Methyl red, Voges – Proskauer and Citrate utilization (IMViC) and Triple sugar iron agar (TSI)<sup>(18)</sup>.

### Total RNA Extraction

A total of 50 *E.coli* ribonucleic acid (RNA) samples were extracted according to the manufacturer's instructions (TransZol Up Plus RNA Kit, TransGen Biotech/China). the samples was then stored in a refrigerator at (-20°C) until use <sup>(19)</sup>.

### cDNA synthesis

This was performed using (5×RT PCR MasterMix, Tynzyme.co., China) <sup>(20)</sup> which contains all the reaction components (the thermo-stable M-MuLV Reverse Transcriptase, Ribonuclease (RNase) Inhibitor, Random primers, Oligo dT Primer, dNTP Mixture, Buffer). The procedure was carried out according to the manufacturer's instructions. the reaction volumes and the components used for reverse transcription as follows; Total RNA/mRNA (10 µl)\5×RT PCR MasterMix (4 µl)\ Nuclease free water (6 µl). Transforming RNA into complementary deoxyribonucleic acid (cDNA) was

performed using a thermal cycling apparatus, which is illustrated within the following steps; step 1(25 °C for 10 minutes), step 2(42 °C for 15 minutes), step 3 (85 °C for 5 seconds). Subsequently, after complete the cDNA synthesis, all tubes were placed in a RT-PCR program for gene expression analysis.

### The quantitative real-time PCR (qPCR) technique

Utilizing the 2- $\Delta\Delta$ CT Livak method, qPCR was performed to identify and measure the comparative expression of gene hemolysin mRNA Transcribing from *E. coli* isolates. A quantitative polymerase chain reaction (qPCR) was performed on a Real-Time PCR equipment from Applied Biosystem, USA. The SYBR green dye qPCR master mixture was used to identify and amplify target genes. The Recombinase A (recA) that code for the housekeeping gene was utilized to normalize the expression of gene. [Table 1](#) presents the designed primers.

**Table 1: Primers of RT-qPCR together along with their sequences**

	Gene	Amplicon size	Primer	Sequence	Reference
1	<i>recA</i> Hosuskeeping	169 bp	F	GAAATCGGCGACTCTCACAT	this study
			R	CGTTACCACCGGTAGTGGTT	
2	<i>hlyA</i>	167bp	F	ACGATGTGGTTTATTCTGGA	this study
			R	CTTCACGTCACCATACATAT	

The qPCR master mix for the *hlyA* targeted gene with housekeeping gene *recA* was prepared following the instructions provided by the (Tinzyme

Co., Limited <sup>TM</sup> 2×Ultra Sybr qPCR Mix (Low Rox),China ) <sup>(20)</sup>, as detailed in [Table 2](#).

**Table 2: qPCR master mix preparation**

Reagent Master Mix	Volume (µl)	Concentration
Forward Primer	0.5	100 pmol
×2Ultra Sybr qPCR Mix (Low Rox)	10	X1
PCR grade water	7	-
Reverse Primer	0.5	100 pmol
cDNA	2	-
Final volum	20	-

(Tinzyme Co., Limited <sup>TM</sup> 2×Ultra Sybr qPCR Mix (Low Rox)

The components of master mix reaction qPCR were transferred in PCR Eppendorf tubes, then were vortexed for three minutes using an Exispin vortex

centrifuge. The tubes were then placed in the MiniOpticon Real-Time PCR System (Applied

Biosystem, USA) under the thermos cycler conditions showed in [Table 3](#).

**Table 3: Real-Time PCR thermocycler conditions**

The Repeat cycle	The Time	The Temperature	qPCR step
1	10 min	95 °C	Pre-denaturation
40	15 s	95 °C	Denaturation
	1 min	60 °C	Annealing/Extension
1	15 s	95 °C	Melting curve analysis
	1 min	60 °C	
	15 s	95 °C	
	15 s	60 °C	

(Tinzyme Co., Limited <sup>TM</sup> 2×Ultra Sybr qPCR Mix (Low Rox)

### Gene expression analysis

The gene expression value was measured using the Livak method <sup>(21)</sup> with the following equation:

$$\Delta CT(\text{target}) = CT_{(\text{target gene})} - CT_{(\text{reference gene})}$$

$$\Delta CT(\text{control}) = CT_{(\text{control gene})} - CT_{(\text{reference gene})}$$

$$\Delta\Delta CT = \Delta CT(\text{target}) - \Delta CT(\text{control})$$

$$\text{Fold change} = 2^{-\Delta\Delta CT}$$

### Statistical Analysis

The T-test for two different samples, SPSS, and GraphPad Prism 9 software were used for statistical analysis at a probability level of (P value  $\leq$  0.05).

## RESULTS

### Detection of hemolysin gene using Real-time PCR

As shown in [Table 4](#), the results revealed that only 18 *E. coli* strains were capable of producing hemolysin:

**Table 4: Number and percentage of hemolysin production isolates**

The source of isolates	Total number of analysed isolates	Analysis of positively isolates with perception %
Urinary tract infection	20	10/20 (50 %)
Diarrhea	20	8/20 (40 %)

**Relative gene expression analysis**

[Table 5](#) and [Table 6](#) show the levels and average gene expression of the HlyA gene in cases of urinary tract infections and diarrhea

**Table 5: Relatively expression of genes analysis for *E. coli* isolates producing gene of hemolysin by utilizing the Livak technique.**

Source of isolates	CT ( <i>hlyA</i> )	CT ( <i>recA</i> )	$\Delta$ CT	Expression for folding Change
UTIs	28.38588	12.30142	16.084459	4.054547
UTIs	29.99131	13.93607	16.055246	4.137485
UTIs	27.66153	12.38249	15.27904	7.085943
UTIs	25.441	9.638002	15.802998	4.928
UTIs	27.41491	11.45567	15.95924	4.422187
UTIs	30.66298	14.83401	15.82897	4.840077
UTIs	30.01022	14.85871	15.151501	7.740887
UTIs	28.66094	13.32844	15.332498	6.828184
UTIs	25.22449	10.18046	15.044036	8.339519
UTIs	29.55656	14.25206	15.304496	6.962011
Diarrhea	30.86153	13.72	17.141531	1.948642
Diarrhea	28.551	12.58172	15.9692797	4.39152
Diarrhea	28.41491	12.03257	16.3823462	3.298143
Diarrhea	29.88298	14.23251	15.6504733	5.477535
Diarrhea	28.10022	12.17912	15.9210932	4.540675
Diarrhea	35.99094	11.50263	16.1943155	3.757269
Diarrhea	30.38449	13.93806	16.4464331	3.15484
Diarrhea	29.00156	12.54538	16.4561763	3.133606

**Table 6: The expression level of the *hlyA* gene and the standard deviation in patients with (UTIs) and diarrhea**

Gene	Case	Number of isolates	Folding( $2^{-\Delta\Delta Ct}$ ) Mean $\pm$ SD	P-Value
<i>hlyA</i>	UTIs	10	5.933 $\pm$ 1.615	0.004
	Diarrhea	8	3.712 $\pm$ 1.081	


(Probability Value of 0.05)

[Figures 1 and 2](#) display the amplification curve and the melting curve of the hemolysin gene in *E.coli*, and [Figure 3](#) illustrate the average gene


expression and the standard deviation of the HlyA gene in both cases (UTIs and diarrhea).



**Fig. 1:** Application of SYBER green in amplifying real-time of PCR plots for the identification of hemolysin gene generating by *E. coli* isolates.



**Fig. 2:** Melt Curve of *hlyA* gene



**Fig. 3:** Analysis the levels of *hlyA* mRNA gene expression. These values have been standardized to represent expression of *recAm* RNA. The bars represent the average and the variability (SD) of two separate controlled experiments, statistically significant at a significance level of P-Value < 0.05.

## DISCUSSION

Factors related to virulence enable *E. coli* to establish itself on the mucosal surface of specific tissues and organs, such as the urinary tract and the intestines. These genetic elements (virulence factors) enhance the pathogenicity and immunological resistance of *E. coli*'s capacity to

generate multiple virulence factors greatly enhances its ability to cause disease (22, 23). The findings of this study indicate that (45 %) of the hemolysin produced by isolates of *E. coli* was quantified utilizing real-time PCR, which closely aligns with the results of (24) that found the percentage was (45.3 %) and (25) which found it was (44 %), while



(Siegfried), <sup>(26-29)</sup> recorded that the percentage was (68.45 %), (68.5 %), (62.5 %) and (75%) respectively. Seasonal and geographical variables significantly influence the abundance of genes associated with virulence among isolates of *E. coli*. There is evidence to suggest that these genes exhibit higher frequencies throughout the summer season rather than winter along with other distinct seasons <sup>(30)</sup>. Isolates of *E. coli* carrying *hlyA* gene were detected using real-time PCR, showing the following percentages of occurrence: (50 %) (10/20) in UTIs cases and (40 %) (8/20) in diarrhea cases. These results was near to results of <sup>(31)</sup> that revealed about (45 %) of the isolates were capable of producing hemolysin toxin onto blood agar and <sup>(32)</sup> who found the percentages was (41.36 %). On the other hands, our results are disagreed with <sup>(33)</sup> and <sup>(34)</sup> who found that the percentage was (23.7 %), (21 %) and (0 %) respectively. While <sup>(35)</sup> recorded a high percentage of (93.7 %), which is higher than our study, furthermore, in Spain <sup>(36)</sup> recorded a rate of (56 %). According to our results, *E. coli* isolates producing hemolysin exhibited higher toxin production (greater activity and effectiveness) in UTIs samples, followed by diarrhea samples. This can be explained by the presence of a large amount of blood in urinary tract due to the destruction of blood vessels. In contrast diarrheic feces contain little or no blood. The presence of blood stimulates *E. coli* isolates to increase the expression levels of the *hlyA* gene, the higher blood levels leading to increased hemolysin secretion<sup>(37)</sup>. Several studies, including one conducted by <sup>(25)</sup> in Egypt, have demonstrated that the prevalence of this gene is higher in cases of UTIs compared to diarrhea cases. This study found that the *hlyA* gene was present in (44 %) of UTI cases, whereas it was found in only (10 %) of diarrhea cases. Many studies have confirmed that Uropathogenic *E. Coli* (UPEC) secrete high concentrations of alpha-hemolysin (*hlyA*), which integrates into the host cell membrane in a calcium-dependent manner, forming pores in umbrella cells

and promoting their lysis. This facilitates bacterial access to iron and nutrients and stimulates exfoliation, exposing deeper layers of the urothelium for colonization and aiding in the spread of bacteria to adjacent cells. Additionally, the production of hemolysin toxins by *hlyA* gene is highly expressed in intracellular bacterial communities (IBCs). In UPEC, these intracellular bacterial communities play a significant role in certain infections, particularly UTIs, where hemolysin production in these communities is deemed essential at this stage of infection <sup>(38)</sup>. Other studies have also confirmed that hemolysin gene enhances invasion and infection in UTIs, with the presence of the *hlyA* gene in the genome of clinical isolates being associated with the severity of infection. Studies have shown that *hlyA* genes are present in (31- 48 %) of *E. coli* strains isolated from cases of uncomplicated UTIs, while their prevalence in isolates from pyelonephritis or urosepsis ranges from (50 to 78 %) <sup>(39)</sup>. Several factors exhibit a substantial impact on the expression of the hemolysin gene in *E. coli* isolates. Specific isolates demonstrate decreased synthesis of hemolysin when exposed to streptomycin, sodium cyanide, rifampin, and nalidixic acid, among other substances. Additionally, hemolysin gene expression reaches its maximum at a pH range of (7-8) <sup>(40)</sup>. Calcium is one of an essential ion for the enhanced production of hemolysin genes. Furthermore, the duration of colony expansion is another crucial determinant in augmenting hemolysin synthesis. Microbial culture in a controlled environment at (37 °C) during (16 hours), a temperature analogous to that of the human body, show increased hemolysin production. Oxygen, glucose, and Iron additives are crucial for promoting the regulating of the *hlyA* gene in isolates of *E. coli*. Hemolytic *E. coli* exhibits increased activity in a liquid medium containing minerals, salts, and hemoglobin. Energy metabolism inhibitors like sodium azide, potassium cyanide, and dinitrophenol inhibit the production and release of hemolysin toxin. likewise, neuroactive



pharmaceuticals and procaine reduce protein synthesis, have a comparable effect. Furthermore, certain drugs, such as nalidixic acid, rifampin, streptomycin, and chloramphenicol, affect gene expression in *E. coli* isolates. Every one of these elements are crucial in regulating the gene expression that produces hemolysin toxin in isolates of *E. coli*, explaining the variation in expression levels among different samples<sup>(27)</sup>. *hlyA* produced by UPEC causes hemolysis of human erythrocytes without the need for toxin interaction with membrane proteins, The high doses of *hlyA* can lyse cells without relying on a receptor, likely because they form pores that disrupt colloidal osmotic pressure. These pores, described as proteolipidic, have their size and stability influenced by the cell membrane composition. Moreover, factors like temperature, exposure time, and toxin concentration have been shown to affect the size of these pores in red blood cells (RBCs)<sup>(39)</sup>. Numerous studies have shown that hemolytic activity, mannose-resistant haemagglutination are more commonly found in UTIs isolates compared to other extra-intestinal and fecal isolates<sup>(41, 42)</sup>.

## CONCLUSION

The current study's results showed that the prevalence of the gene responsible for the secretion of hemolysin toxins by *E. coli* is higher in cases of UTIs than in cases of diarrhea. The study also demonstrated that the gene expression of *hlyA* was more pronounced in UTIs. *hlyA* gene expression increased in *E. coli* in response to the presence of blood in the surrounding environment. To summarize, the release of the toxin of hemolysin from *E. coli* is influenced by various both inside and outside environmental conditions that dictate the level of gene expression.

**Conflict of interests:** The authors declared no conflicting interests.

**Sources of funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Author contribution:** Authors contributed equally in the study.

## REFERENCES

- Hoffmann TC, Bakhit M, Del Mar C. Uncomplicated urinary tract infection in women. *Bmj*. 2021;372. <https://doi.org/10.1136/bmj.n725>
- Singh V. Textbook of Anatomy: Upper Limb and Thorax, Vol 1, 3rd Updated Edition, eBook: Elsevier Health Sciences; 2020.
- Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. *American journal of obstetrics and gynecology*. 2018;219(1):40-51. <https://doi.org/10.1016/j.ajog.2017.12.231>
- Obaid HM, Juma SA. Urinary PH and crystals association with bacterial isolates in patients with urinary tract infection. *Tikrit Journal of Pure Science*. 2015;20(2):7-13. <https://doi.org/10.25130/tjps.v20i2.1151>
- Chiță T, Timar B, Muntean D, Bădițoiu L, Horhat F, Hogeia E, et al. Urinary tract infections in Romanian patients with diabetes: prevalence, etiology, and risk factors. *Therapeutics and Clinical Risk Management*. 2016:1-7. <https://doi.org/10.2147/TCRM.S123226>
- Druwish SN. The Role of TLR-4, TIM-3, and IL-6 Along with Bacterial Species in Urinary Tract Infections in Pregnant Women: Tikrit University; 2021.
- Scribano D, Sarshar M, Fettucciari L, Ambrosi C. Urinary tract infections: Can we prevent uropathogenic *Escherichia coli* infection with dietary intervention? : Hogrefe AG; 2021. <https://doi.org/10.1024/0300-9831/a000704>
- Czajkowski K, Broś-Konopielko M, Teliga-Czajkowska J. Urinary tract infection in women. *Menopause Review/Przegląd Menopauzalny*. 2021;20(1):40-7. <https://doi.org/10.5114/pm.2021.105382>
- Oyaert M, Van Meensel B, Cartuyvels R, Frans J, Laffut W, Vandecandelaere P, et al. Laboratory diagnosis of urinary tract infections:

Towards a BILULU consensus guideline. Journal of microbiological methods. 2018;146:92-9. <https://doi.org/10.1016/j.mimet.2018.02.006>

10. WHO. Diarrheal disease: fact sheet on diarrheal disease provides key facts and information on scope, causes, prevention and treatment. 2013.

11. Bern C. Impact of diarrheal disease worldwide. Viral infections of gastrointestinal tract. 1994;1-26.

12. Gidudu J, Sack D, Pina M, Hudson M, Kohl K, Bishop P, et al. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(5):1053.

<https://doi.org/10.1016/j.vaccine.2010.11.065>

13. Davidson G, Barnes G, Bass D, Cohen M, Fasano A, Fontaine O, et al. Infectious diarrhea in children: working group report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of pediatric gastroenterology and nutrition. 2002;35:S143-S50. <https://doi.org/10.1002/jpn3.12008>

14. Caetano BDL, Domingos MdO, da Silva MA, da Silva JCA, Polatto JM, Montoni F, et al. In silico prediction and design of uropathogenic Escherichia coli alpha-hemolysin generate a soluble and hemolytic recombinant toxin. Microorganisms. 2022;10(1):172.

<https://doi.org/10.3390/microorganisms10010172>

15. Nunes PHS, Valiatti TB, Santos ACdM, Nascimento JAdS, Santos-Neto JF, Rocchetti TT, et al. Evaluation of the pathogenic potential of Escherichia coli strains isolated from eye infections. Microorganisms. 2022;10(6):1084.

<https://doi.org/10.3390/microorganisms10061084>

16. Abdulwahhab AM, Khalaf KJ. Effect of cultivation conditions on hemolysin production from clinical isolates of Serratia marcescens. Al-Mustansiriyah J Sci. 2022;33:6-14. <https://doi.org/10.23851/mjs.v33i1.1080>

17. Beutin L, Aleksic' S, Zimmermann S, Gleier K. Virulence factors and phenotypical traits of verotoxigenic strains of Escherichia coli isolated

from human patients in Germany. Medical microbiology and immunology. 1994;183:13-21. <https://doi.org/10.1007/BF00193627>

18. Leber AL. Clinical microbiology procedures handbook: John Wiley & Sons; 2020.

19. ransZolUp Plus RNA Kit, Cat No. ER501China: TransGen Biotech; 2024 [Available from: <http://www.transgenbiotech.com/>.

20. 2× Ultra Sybr qPCR Mix (low ROX), Product No. PCM33L.: Tinzyme Co., Limited; 2024.

21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup> ΔΔCT method. methods. 2001;25(4):402-8.

<https://doi.org/10.1006/meth.2001.1262>

22. Emody L, Kerenyi M, Nagy G. Virulence factors of uropathogenic Escherichia coli. International journal of antimicrobial agents. 2003;22:29-33. [https://doi.org/10.1016/S0924-8579\(03\)00236-X](https://doi.org/10.1016/S0924-8579(03)00236-X)

23. Raksha R, Srinivasa H, Macaden R. Occurrence and characterisation of uropathogenic Escherichia coli in urinary tract infections. Indian journal of medical microbiology. 2003;21(2):102-7. [https://doi.org/10.1016/S0255-0857\(21\)03130-3](https://doi.org/10.1016/S0255-0857(21)03130-3)

24. Abd El-Baky RM, Ibrahim RA, Mohamed DS, Ahmed EF, Hashem ZS. Prevalence of virulence genes and their association with antimicrobial resistance among pathogenic E. coli isolated from Egyptian patients with different clinical infections. Infection and Drug Resistance. 2020;1221-36. <https://doi.org/10.2147/IDR.S241073>

25. Osman K, Mustafa A, Elhariri M, AbdElhamed G. Identification of serotypes and virulence markers of Escherichia coli isolated from human stool and urine samples in Egypt. Indian Journal of Medical Microbiology. 2012;30(3):308-13. <https://doi.org/10.4103/0255-0857.99492>

26. Al-daan WRT, Ali SAA-R, kadhim Al-Saffar A. Effect of Piper cubeba Fruits Extract on Bacteriocin Production of E. coli Isolated from Patient with Urinary Tract Infection. Biomedical &

- Pharmacology Journal. 2017;10(1):111.  
<http://dx.doi.org/10.13005/bpi/1088>
27. Al-Hadithi H. Molecular detection of Hemolysin in Escherichia coli and attempt to inhibition by using the Probiotics. Tikrit Journal of Pure Science. 2018;23(6):79-90.  
<http://dx.doi.org/10.10.25/tjps/23.20018.09288>
28. Nasser HH, Ismaeel GK, Majeed NM. Gene expression study of pathogenic hemolysin producing E. Coli isolated from cattle by using reverse transcription real-time PCR. Al-Qadisiyah. J Vet Med Sci. 2018;17(2):53-60.  
<https://doi.org/10.29079/vol17iss2art505>
29. Siegfried L, Kmeřová M, Puzova H, Molokáčová M, Filka J. Virulence-associated factors in Escherichia coli strains isolated from children with urinary tract infections. Journal of medical microbiology. 1994;41(2):127-32.  
<https://doi.org/10.1099/00222615-41-2-127>
30. Rahimi E, Khamesipour F, Yazdi F, Momtaz H. Isolation and characterization of enterohaemorrhagic Escherichia coli O157: H7 and EHEC O157: NM from raw bovine, camel, water buffalo, caprine and ovine milk in Iran. Kafkas Üniversitesi Veteriner Fakültesi Dergisi. 2012;18(4).  
<https://doi.org/10.9775/kvfd.2011.5738>
31. Ali JA. Hemolysin and Bacteriocin production of E. coli isolated from urinary tract infection. Journal of Babylon University/pure and Applied Science. 2012;20(5):1448-51.  
<https://www.iasj.net/iasj/download/502a1fa48b4141e0>
32. Sharma S, Bhat G, Shenoy S. Virulence factors and drug resistance in Escherichia coli isolated from extraintestinal infections. Indian journal of medical microbiology. 2007;25(4):369-73.  
[https://doi.org/10.1016/S0255-0857\(21\)02053-3](https://doi.org/10.1016/S0255-0857(21)02053-3)
33. Murase K, Ooka T, Iguchi A, Ogura Y, Nakayama K, Asadulghani M, et al. Haemolysin E- and enterohaemolysin-derived haemolytic activity of O55/O157 strains and other Escherichia coli lineages. Microbiology. 2012;158(3):746-58.  
<https://doi.org/10.1099/mic.0.054775-0>
34. Kausar Y, Chunchanur SK, Nadagir SD, Halesh L, Chandrasekhar M. Virulence factors, serotypes and antimicrobial susceptibility pattern of Escherichia coli in urinary tract infections. Al Ameen J Med Sci. 2009;2(1):47-51.  
<https://sid.ir/paper/653261/en>
35. Marques L, Abe CM, Griffin PM, Gomes T. Association between alpha-hemolysin production and HeLa cell-detaching activity in fecal isolates of Escherichia coli. Journal of clinical microbiology. 1995;33(10):2707-9.  
<https://doi.org/10.1128/jcm.33.10.2707-2709.1995>
36. Blanco J, Blanco M, Blanco JE, Mora A, Gonzalez EA, Bernardez MI, et al. Verotoxin-producing Escherichia coli in Spain: prevalence, serotypes, and virulence genes of O157: H7 and non-O157 VTEC in ruminants, raw beef products, and humans. Experimental biology and medicine. 2003;228(4):345-51.  
<https://doi.org/10.1177/153537020322800403>
37. Wang G, Clark CG, Rodgers FG. Detection in Escherichia coli of the genes encoding the major virulence factors, the genes defining the O157: H7 serotype, and components of the type 2 Shiga toxin family by multiplex PCR. Journal of clinical microbiology. 2002;40(10):3613-9.  
<https://doi.org/10.1128/jcm.40.10.3613-3619.2002>
38. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews microbiology. 2015;13(5):269-84.  
<https://doi.org/10.1038/nrmicro3432>
39. Cané L, Saffioti NA, Genetet S, Millone MAD, Ostuni MA, Schwarzbaum PJ, et al. Alpha hemolysin of E. coli induces hemolysis of human erythrocytes independently of toxin interaction with membrane proteins. Biochimie. 2024;216:3-13.  
<https://doi.org/10.1016/j.biochi.2023.10.008>
40. Burnside K, Lembo A, de Los Reyes M, Iliuk A, BinhTran N-T, Connelly JE, et al. Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine

kinase and phosphatase. PloS one. 2010;5(6):e11071.

<https://doi.org/10.1371/journal.pone.0011071>

41. Fakruddin M, Mazumdar RM, Chowdhury A, Mannan KSB. A preliminary study on virulence factors & antimicrobial resistance in extra-intestinal pathogenic *Escherichia coli* (ExPEC) in Bangladesh. Indian Journal of Medical Research.

2013;137(5):988-90.

<http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3734695>

42. Najjar AG, Nejad MM, Mansouri S. The comparison between virulence factors of *Escherichia coli* isolated from urinary tract infections and fecal flora. Research in pharmaceutical Sciences. 2007;1(2):99-103. <http://rps.mui.ac.ir/index.php/jrps/article/view/18/16>